Top Markets
#1 Siren Siren +38.80%
#2 RedStone RedStone +24.34%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.68%
#4 Ocean Protocol Ocean Protocol +15.45%
#5 KUB Coin KUB Coin +14.83%
#6 Perle Perle +12.11%
#7 Nosana Nosana +10.27%
#8 Wiki Cat Wiki Cat +9.55%
#9 Nockchain Nockchain +8.82%
#10 Arowana Arowana +8.55%
Coin of the day
Siren Siren
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
CytoMed Therapeutics Limited CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTC
Clasificación en acciones #32327
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical... CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Precio por acción
$0.88
Última sincronización: 2026-08-17
Capitalización bursátil
$10.41M
Cambio (1 día)
-7.26%
Cambio (1 año)
-50.56%
País
SG
Comercio CytoMed Therapeutics Limited (GDTC)

Categoría

Healthcare
Ratio P/B de CytoMed Therapeutics Limited (GDTC)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de CytoMed Therapeutics Limited, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de CytoMed Therapeutics Limited desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR